CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for RegeneRx Biopharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

RegeneRx Biopharmaceuticals Inc
15245 SHADY GROVE ROAD, SUITE 470
Phone: (301) 208-9191p:301 208-9191 ROCKVILLE, MD  20850  United States Ticker: RGRXRGRX

Business Summary
RegeneRx Biopharmaceuticals, Inc. (RegeneRx) is a biopharmaceutical company. The RegeneRx is focused on the development of a therapeutic peptide Thymosin beta 4(Tb4) for tissue and organ protection, repair, and regeneration. RegeneRx operates in the development and marketing of Tb4, an amino acid peptide. Tb4 is a synthetic copy of a naturally occurring 43-amino acid peptid originally isolated from bovine thymus glands. The Company's product candidates in clinical development includes RGN-259, RGN-352, and RGN-137. The Company's RGN -259 is a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases. Its RGN-137 is a topical gel for dermal wounds and reduction of scar tissue.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/202312/31/2022YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Founder, Chief Scientific Officer Allan L.Goldstein 85 1/1/1982 1/1/1982
President, Chief Executive Officer, Director J. J.Finkelstein 70 1/1/2002 1/1/1984
Director AlessandroNoseda 64 4/1/2019 4/1/2019
3 additional Officers and Directors records available in full report.

Business Names
Business Name
RegeneRx Biopharmaceut.
RGRX
RGRXD

General Information
Number of Employees: 2 (As of 12/31/2022)
Outstanding Shares: 1,496,966 (As of 10/18/2023)
Shareholders: 4,037
Stock Exchange: OTC
Federal Tax Id: 521253406
Fax Number: (301) 208-9194


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, November 30, 2024